Annexon Q3 net loss widens to $54.9 mln

Annexon

10/11/2025 21:20

Overview

Annexon reports Q3 net loss of $54.9 mln, with increased R&D expenses

Company maintains strong cash position, extending operations into 2027

Result Drivers

R&D expenses were $49.7 million for the quarter ended September 30, 2025, compared to $30.1 million for the quarter ended September 30, 2024.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$54.92 mln
Q3 Basic EPS
-$0.37
Q3 Cash & Investments
$188.70 mln
Q3 Income From Operations
-$57.02 mln
Q3 Operating Expenses
$57.02 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Annexon Inc is $11.00, about 73.8% above its November 7 closing price of $2.88

Press Release: ID:nGNX92dpPv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)